Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Philip Carter, Costi Alifrangis, Biancastella Cereser, Pramodh Chandrasinghe, Lisa Del Bel Belluz, Thomas Herzog, Joel Levitan, Nina Moderau, Lee Schwartzberg, Neha Tabassum, Jinrui Wen, Jonathan Krell, Justin Stebbing

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers. Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations. The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001).

Original languageEnglish (US)
Pages (from-to)9456-9467
Number of pages12
JournalOncotarget
Volume9
Issue number10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Intelligence
Immunohistochemistry
DNA Repair
Neoplasms
Biomarkers
Urologic Neoplasms
Neuroendocrine Tumors
Biological Science Disciplines
Androgen Receptors
P-Glycoprotein
Progesterone Receptors
Therapeutics
DNA Sequence Analysis
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Adenocarcinoma
Research Design
Breast Neoplasms
Carcinoma
Physicians

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Belluz, L. D. B., Herzog, T., ... Stebbing, J. (2018). Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? Oncotarget, 9(10), 9456-9467. https://doi.org/10.18632/oncotarget.24258

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? / Carter, Philip; Alifrangis, Costi; Cereser, Biancastella; Chandrasinghe, Pramodh; Belluz, Lisa Del Bel; Herzog, Thomas; Levitan, Joel; Moderau, Nina; Schwartzberg, Lee; Tabassum, Neha; Wen, Jinrui; Krell, Jonathan; Stebbing, Justin.

In: Oncotarget, Vol. 9, No. 10, 01.01.2018, p. 9456-9467.

Research output: Contribution to journalArticle

Carter, P, Alifrangis, C, Cereser, B, Chandrasinghe, P, Belluz, LDB, Herzog, T, Levitan, J, Moderau, N, Schwartzberg, L, Tabassum, N, Wen, J, Krell, J & Stebbing, J 2018, 'Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?', Oncotarget, vol. 9, no. 10, pp. 9456-9467. https://doi.org/10.18632/oncotarget.24258
Carter, Philip ; Alifrangis, Costi ; Cereser, Biancastella ; Chandrasinghe, Pramodh ; Belluz, Lisa Del Bel ; Herzog, Thomas ; Levitan, Joel ; Moderau, Nina ; Schwartzberg, Lee ; Tabassum, Neha ; Wen, Jinrui ; Krell, Jonathan ; Stebbing, Justin. / Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?. In: Oncotarget. 2018 ; Vol. 9, No. 10. pp. 9456-9467.
@article{9afd6762c3c04a7e89078373627aadf3,
title = "Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?",
abstract = "We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers. Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations. The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34{\%} of patients were deceased at the completion of monitoring, whereas this was 47{\%} in the unmatched group (P = 0.0001).",
author = "Philip Carter and Costi Alifrangis and Biancastella Cereser and Pramodh Chandrasinghe and Belluz, {Lisa Del Bel} and Thomas Herzog and Joel Levitan and Nina Moderau and Lee Schwartzberg and Neha Tabassum and Jinrui Wen and Jonathan Krell and Justin Stebbing",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24258",
language = "English (US)",
volume = "9",
pages = "9456--9467",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

AU - Carter, Philip

AU - Alifrangis, Costi

AU - Cereser, Biancastella

AU - Chandrasinghe, Pramodh

AU - Belluz, Lisa Del Bel

AU - Herzog, Thomas

AU - Levitan, Joel

AU - Moderau, Nina

AU - Schwartzberg, Lee

AU - Tabassum, Neha

AU - Wen, Jinrui

AU - Krell, Jonathan

AU - Stebbing, Justin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers. Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations. The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001).

AB - We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers. Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations. The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001).

UR - http://www.scopus.com/inward/record.url?scp=85041387603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041387603&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24258

DO - 10.18632/oncotarget.24258

M3 - Article

VL - 9

SP - 9456

EP - 9467

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -